Treatment Outcomes after Postoperative Radiotherapy in Triple-Negative Breast Cancer: Multi-Institutional Retrospective Study (KROG 17-05)
- Author(s)
- Jin Hee Kim; Sang Jun Byun; Myeongsoo Kim; Kyung Hwan Shin; Dong Yun Kim; Han Byoel Lee; Tae Hyun Kim; Yeon Joo Kim; Yong Bae Kim; Jee Suk Chang; Kyubo Kim; Sun Young Lee
- Keimyung Author(s)
- Kim, Jin Hee
- Department
- Dept. of Radiation Oncology (방사선종양학)
- Journal Title
- J Pers Med
- Issued Date
- 2024
- Volume
- 14
- Issue
- 9
- Keyword
- triple-negative breast neoplasms; radiotherapy; failure pattern; survival; prognostic factors
- Abstract
- Background:
We designed a multi-institutional retrospective study to investigate the previously unreported failure pattern, survivals, and prognostic factors after postoperative radiotherapy (PORT) in triple negative breast cancer (TNBC) patients in South Korea.
Materials and Methods:
We retrospectively reviewed 699 patients with TNBC who underwent PORT at six institutions between 2008 and 2010. The median follow-up period was 94 months (range: 7–192 months). There were 216, 380, and 100 patients in stages I, II, and III, respectively.
Results:
After 94 months post-treatment, all patients with pathologic complete remission after neoadjuvant chemotherapy were alive without any failure. Distant metastasis was the main cause of failure. The 5-year overall survival rate was 91.4%, 5-year loco-regional relapse-free survival rate (LRRFS) was 92.3%, 5-year distant metastasis-free survival rate (DMFS) was 89.4%, and 5-year disease-free survival rate (DFS) was 85.2%. On multivariate (Cox) analysis, T and N stages were significant prognostic factors for survival, and lympho-vascular invasion (LVI) was a significant factor for LRRFS and DMFS. Ki-67 expression was significantly associated with LRRFS and DFS.
Conclusion:
We verified that T and N stages, LVI, and Ki-67 expression were significantly associated with survival outcomes after PORT in TNBC.
- 공개 및 라이선스
-
- 파일 목록
-
Items in Repository are protected by copyright, with all rights reserved, unless otherwise indicated.